366 related articles for article (PubMed ID: 22855332)
1. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
J Clin Endocrinol Metab; 2012 Oct; 97(10):3799-806. PubMed ID: 22855332
[TBL] [Abstract][Full Text] [Related]
2. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
Ahrén B; Schweizer A; Dejager S; Dunning BE; Nilsson PM; Persson M; Foley JE
J Clin Endocrinol Metab; 2009 Apr; 94(4):1236-43. PubMed ID: 19174497
[TBL] [Abstract][Full Text] [Related]
3. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
Diabetes Obes Metab; 2014 Sep; 16(9):812-8. PubMed ID: 24612221
[TBL] [Abstract][Full Text] [Related]
4. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
El-Ouaghlidi A; Rehring E; Holst JJ; Schweizer A; Foley J; Holmes D; Nauck MA
J Clin Endocrinol Metab; 2007 Nov; 92(11):4165-71. PubMed ID: 17698900
[TBL] [Abstract][Full Text] [Related]
5. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.
Scherbaum WA; Schweizer A; Mari A; Nilsson PM; Lalanne G; Jauffret S; Foley JE
Diabetes Obes Metab; 2008 Aug; 10(8):675-82. PubMed ID: 18248490
[TBL] [Abstract][Full Text] [Related]
7. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
Pan C; Yang W; Barona JP; Wang Y; Niggli M; Mohideen P; Wang Y; Foley JE
Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
[TBL] [Abstract][Full Text] [Related]
8. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
[TBL] [Abstract][Full Text] [Related]
9. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Azuma K; Rádiková Z; Mancino J; Toledo FG; Thomas E; Kangani C; Dalla Man C; Cobelli C; Holst JJ; Deacon CF; He Y; Ligueros-Saylan M; Serra D; Foley JE; Kelley DE
J Clin Endocrinol Metab; 2008 Feb; 93(2):459-64. PubMed ID: 18042650
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
Serra D; He YL; Bullock J; Riviere GJ; Balez S; Schwartz S; Wang Y; Ligueros-Saylan M; Jarugula V; Dole WP
Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589
[TBL] [Abstract][Full Text] [Related]
11. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
[TBL] [Abstract][Full Text] [Related]
12. Update: vildagliptin for the treatment of Type 2 diabetes.
Garber AJ; Sharma MD
Expert Opin Investig Drugs; 2008 Jan; 17(1):105-13. PubMed ID: 18095923
[TBL] [Abstract][Full Text] [Related]
13. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
[TBL] [Abstract][Full Text] [Related]
15. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
16. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
17. Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.
He YL; Ito H; Yamaguchi M; Terao S; Shimada S; Irie S; Sekiguchi K
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):237-47. PubMed ID: 22456294
[TBL] [Abstract][Full Text] [Related]
18. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
Schweizer A; Foley JE; Kothny W; Ahrén B
Vasc Health Risk Manag; 2013; 9():57-64. PubMed ID: 23431062
[TBL] [Abstract][Full Text] [Related]
19. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
Kanazawa I; Tanaka KI; Notsu M; Tanaka S; Kiyohara N; Koike S; Yamane Y; Tada Y; Sasaki M; Yamauchi M; Sugimoto T
Diabetes Res Clin Pract; 2017 Jan; 123():9-17. PubMed ID: 27914297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
